Hematologic Abnormalities Associated With Lung Carcinoma

Shafiq, Mājid; Venkateshiah, Saiprakash B.

doi:10.4187/respcare.00944

Cited by 8 publications

(14 citation statements)

References 10 publications

(12 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Thrombocytosis in lung cancer may be due to either humoral factors secreted by tumour cells or it is a part of systemic inflammatory reaction. 7,37 A similar prevalence of thrombocytosis (13-32%) had been reported in previous studies. 34,38 While, other reported a higher prevalence of thrombocytosis (50-60%) without showing any significant differences between pathological types.…”

Section: Discussionsupporting

confidence: 84%

“…4,6 Anemia and thrombocytosis have been reported in patients with solid tumours, mainly lung cancer and colorectal cancer. 7 It is the most common hematologic abnormality in cancer patients, and around 50% of patients will develop anemia at some point. 8 Thrombocytosis or even upper normal platelet counts have been shown to be associated with advanced stages of cancer and to be a negative prognostic marker.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Clinical, radiological, laboratory and bronchoscopic features characterizing each type of bronchogenic carcinoma

Hafez¹,

Abo-Elkheir²

2017

Int J Res Med Sci

View full text Add to dashboard Cite

Background: To analyse the clinical, radiological, laboratory, and bronchoscopic findings characterizing each type of bronchogenic carcinoma.Methods: A cross-sectional study was conducted on 123 bronchogenic carcinoma patients. They were subjected to history taking, laboratory investigations, computed tomographic scan and fiberoptic bronchoscopy.Results: The mean age of the patients was 56.9±6.7 years, 76.4% were males and 78.9% were smokers. Most of them were symptomatic, adenocarcinoma (ADC) being the highest symptomatic one. Expectoration, fingers clubbing, and fever were common in ADC and small cell lung cancer (SCLC). Dyspnea, haemoptysis, dysphonia, dysphagia, vocal cord paralysis, anorexia and weight loss were common in SCLC and squamous cell carcinoma (SCC). Deep venous thrombosis was common in ADC and SCC. Mass lesion, atelectasis, chest wall invasion and elevated hemidiaphragm were common in SCLC and SCC. Ipsilateral mediastinal lymph nodes enlargement, cavitary lesion, and apical lesion were common in SCC and ADC. Contralateral mediastinal lymph nodes enlargement was common in SCLC. Nodular lesion, consolidation and pleural effusion were common in ADC. Hypercalcemia and hyponatremia were common in SCC. Malignant pleural effusion was common in ADC. Most of the patients had bronchoscopically-visible lesions; SCLC and SCC being the highest visible types. Most of the SCC and SCLC were centrally located, while LCC and ADC were mainly peripherally located. Most of cases were diagnosed via bronchoscopy. More than half of the studied cases were inoperable at presentation, especially SCLC and SCC.Conclusions: The 4 pathological types are distinguished from each other’s by certain clinical, radiological, laboratory and bronchoscopic features.

show abstract

Section: Discussionsupporting

confidence: 84%

Section: Introductionmentioning

confidence: 99%

Clinical, radiological, laboratory and bronchoscopic features characterizing each type of bronchogenic carcinoma

Hafez¹,

Abo-Elkheir²

2017

Int J Res Med Sci

View full text Add to dashboard Cite

show abstract

“…Studies have reported its incidence as 50-60%, which is much higher than that seen in colorectal and breast cancers (around 10-20% each) (11). After anticancer treatment, anemia was reported in 54% of patients and as many as 71% of patients were anemic at some time.…”

Section: Discussionmentioning

confidence: 95%

“…It is associated with fatigue in 3 of every 4 cancer patients, as measured with the general version of the Functional Assessment of Cancer Therapy (FACT-G) questionnaire, and decreases the quality of life (QOL). In a telephone survey of 419 patients, 61% of cancer patients declared fatigue affected their daily lives more than pain (11 breath, lightheadedness and dizziness were the other symptoms of anemia reported by cancer patients (13). Anemia is also associated with a higher cancer recurrence rate and shorter survival after radiotherapy.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Anemia and Systemic Inflammation in Advanced Non-Small Cell Lung Cancer

Karadağ¹,

Gülen²,

Karul³

2013

Solunum

View full text Add to dashboard Cite

Objective: We assessed hematological variables and various markers of systemic inflammation in a population of previously untreated patients with advanced non-small cell lung cancer (NSCLC) and healthy controls to evaluate the frequency of anemia and its correlation with systemic inflammation.Methods: In patients with untreated advanced NSCLC and control subjects, levels of hemoglobin (Hb), serum levels of acute phase reactants (APR) including C-reactive protein (CRP) and inflammatory cytokines (TNF-α, leptin and osteopontin) were assessed. They were analysed by Pearson's correlation analysis and Mann-Whitney U test.Results: Sixty-three male NSCLC patients with a mean age of 65.6±9.8 years were admitted to the study and 25 male healthy volunteers of the same age range were admitted as the control group. Twenty-five (40%) NSCLC patients had anemia during diagnosis of lung carcinoma. Positive APR CRP, leucocyte, thrombocyte, ferritin and fibrinogen were higher in the NSCLC group than the controls (p<0.001, p=0.042, p<0.001, p=0.009, p<0.001). Serum albumin (which is a negative APR) was lower in the cancer group (p<0.001). Osteopontin was higher in the cancer group (p<0.001) but there were no difference in leptin and TNF-α concentrations. There was no correlation between Hb and stage of the disease, performance score of patients or cytokines. Serum CRP and thrombocyte concentrations were higher in cancer patients with anemia than those without anemia (p=0.012, p<0.001).In the anemic subgroup of lung cancer patients, again Hb inversely correlated with CRP and thrombocyte and positively correlated with albumin.Conclusion: This evidence confirms that anemia is common in lung cancer and its presence is related to systemic inflammation.Keywords: Acute phase reactants, anemia, C-reactive protein, cytokines, lung cancer, systemic inflammation ÖZETAmaç: Önceden tedavi görmemiş ileri evre küçük hücreli-dışı akciğer karsinomlu (KHDAK) bir grup hastada ve sağlıklı kontrol grubunda anemi sıklığını ve sistemik inflamasyonla ilişkisini değerlendirmek için hematolojik değişkenleri ve çeşitli sistemik inflamasyon göstergelerini araştırdık.Yöntemler: Henüz tedavi almamış KHDAK olguları ve kontrol gruplarında hemoglobin (Hb), C-reaktif protein (CRP) de dahil olmak üzere serum akut faz reaktanları (AFR) ve inflamatuvar sitokin (TNF-α, leptin ve osteopontin) düzeyleri ölçüldü. Sonuçlar Pearson's korelasyon testi ve Mann-Whitney U tesi kullanılarak değer-lendirildi.Bulgular: Çalışmaya yaş ortalamaları 65,6±9,8 yıl olan 63 erkek KHDAK olgusu dahil edildi. Aynı yaş grubunda olan 25 sağlıklı gönüllü kontrol grubu olarak alındı.Yirmi beş (%40) KHDAK olgusunda tanı konduğu sırada anemi mevcut idi. Pozitif AFR olan CRP, lökosit, trombosit, ferritin ve fibrinojen düzeyleri KHDAK olgularında kontrol grubundan yüksekti (p<0,001, p=0,042, p<0,001, p=0,009, p<0,001). Serum albümini (negatif bir AFR) kanser grubunda daha düşüktü (p<0,001). Osteopontin kanser grubunda daha yüksek (p<0,001) iken leptin ve TNF-α konsantrasyonlarında fark yok...

show abstract

Stimulatory versus suppressive effects of GM-CSF on tumor progression in multiple cancer types

2016

View full text Add to dashboard Cite

Granulocyte-macrophage colony-stimulating factor (GM-CSF, also called CSF-2) is best known for its critical role in immune modulation and hematopoiesis. A large body of experimental evidence indicates that GM-CSF, which is frequently upregulated in multiple types of human cancers, effectively marks cancer cells with a ‘danger flag' for the immune system. In this context, most studies have focused on its function as an immunomodulator, namely its ability to stimulate dendritic cell (DC) maturation and monocyte/macrophage activity. However, recent studies have suggested that GM-CSF also promotes immune-independent tumor progression by supporting tumor microenvironments and stimulating tumor growth and metastasis. Although some studies have suggested that GM-CSF has inhibitory effects on tumor growth and metastasis, an even greater number of studies show that GM-CSF exerts stimulatory effects on tumor progression. In this review, we summarize a number of findings to provide the currently available information regarding the anticancer immune response of GM-CSG. We then discuss the potential roles of GM-CSF in the progression of multiple types of cancer to provide insights into some of the complexities of its clinical applications.

show abstract

Hematologic Abnormalities Associated With Lung Carcinoma

Cited by 8 publications

References 10 publications

Clinical, radiological, laboratory and bronchoscopic features characterizing each type of bronchogenic carcinoma

Clinical, radiological, laboratory and bronchoscopic features characterizing each type of bronchogenic carcinoma

Anemia and Systemic Inflammation in Advanced Non-Small Cell Lung Cancer

Stimulatory versus suppressive effects of GM-CSF on tumor progression in multiple cancer types

Contact Info

Product

Resources

About